Drug intelligence / Profile preview

T2

Development stage: Unknown
Administration: Oral

Overview

T2 is a chloroform/methanol extract derived from the traditional Chinese medicine Tripterygium wilfordii Hook F (TWHF). It has demonstrated both immunomodulatory and anti-inflammatory activities. Its major component, triptolide, has shown potential in preventing chronic colitis in animal studies. T2 is being investigated for its efficacy and safety in conditions such as Crohn's disease and rheumatoid arthritis.

Brand names: T2T-2T 2
Other names: chloroform/methanol extract Tripterygium wilfordii Hook FTWHF extract

Targets

COXMOR (Mu opioid receptor)

Beyond the preview

Go deeper on T2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T2.

Explore the full profile